Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 7.03 is 57% above its 5-year average of 4.49, near the high end of its 5-year range (1.54–7.50).
As of the fiscal period ended Tuesday, June 30, 2026. 44.14% above its 12-month average of 4.88.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 7.03.
CURRENT RATIO
7.03
CURRENT RATIO AVG TTM
4.88
CURRENT RATIO AVG 3Y
3.95
CURRENT RATIO AVG 5Y
4.49
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+44.14%
CURRENT VS 3Y AVG
+78.11%
CURRENT VS 5Y AVG
+56.50%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.34
median of 516 covered companies
CURRENT VS SECTOR MEDIAN
+110.40%
vs the sector median at left
Cognition Therapeutics, Inc.
Market Cap
$84.13M
Current Ratio
7.03
TTM Avg
4.88
3Y Avg
3.95
5Y Avg
4.49
Market Cap
$84.79M
Current Ratio
1.98
TTM Avg
0.65
3Y Avg
1.44
5Y Avg
2.62
Market Cap
$85.60M
Current Ratio
7.99
TTM Avg
9.12
3Y Avg
12.06
5Y Avg
14.25
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cognition Therapeutics, Inc. (CGTX) | $84.13M | 7.03 | 4.88 | 3.95 | 4.49 |
| Humacyte, Inc. (HUMA)vs › | $84.17M | 6.21 | 3.04 | 4.62 | 7.16 |
| LENSAR Inc (LNSR)vs › | $83.92M | 2.39 | 1.97 | 2.72 | 3.82 |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $84.79M | 1.98 | 0.65 | 1.44 | 2.62 |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $85.60M | 7.99 | 9.12 | 12.06 | 14.25 |
| Equillium, Inc. (EQ)vs › | $87.88M | 23.40 | 7.13 | 4.61 | 6.59 |
| CareCloud, Inc. (CCLD)vs › | $87.96M | 1.02 | 1.16 | 1.22 | 1.27 |
| ImmuCell Corporation (ICCC)vs › | $88.21M | 4.75 | 3.83 | 3.74 | 4.48 |
| Citius Oncology, Inc. (CTOR)vs › | $79.78M | 0.73 | 0.45 | 0.43 | 0.43 |
| Cardiff Oncology, Inc. (CRDF)vs › | $88.63M | 3.30 | 5.38 | 8.10 | 12.75 |
Current Ratio
7.03
Quick Ratio
7.03
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 7.03 |
| 2026-03-31 | 5.92 |
| 2025-12-31 | 3.45 |
| 2025-09-30 | 6.44 |
| 2025-06-30 | 1.54 |
| 2025-03-31 | 2.09 |
| 2024-12-31 | 2.65 |
| 2024-09-30 | 2.11 |
| 2024-06-30 | 3.07 |
| 2024-03-31 | 4.00 |
| 2023-12-31 | 3.37 |
| 2023-09-30 | 4.38 |
| 2023-06-30 | 5.25 |
| 2023-03-31 | 5.73 |
| 2022-12-31 | 6.11 |
| 2022-09-30 | 4.20 |
| 2022-06-30 | 7.44 |
| 2022-03-31 | 7.38 |
| 2021-12-31 | 7.50 |
| 2021-09-30 | 2.27 |
| 2021-06-30 | 2.36 |
| 2021-03-31 | 3.68 |
| 2020-12-31 | 2.13 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
